My thought are.
No trifecta but a very good Double.
1/Response rate was Higher with sirt by 7.4%
2/Both the side effect profile and QUALITY OF LIFE was much better over time in the sirt group.
3/ if patient Re not tolerant or have contraindications for Sorafenib therapy there are currently no standard of care .
Paragraph 2 an 3 is the key for me.
Yes i get it the primary end point did not show an overall survival superiority
I the end quality of life is far more important.
Glta
My thought are. No trifecta but a very good Double. 1/Response...
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
15.3¢ |
Change
-0.003(1.61%) |
Mkt cap ! $64.72M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.5¢ | 15.0¢ | $58.98K | 380.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 2627800 | 15.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.5¢ | 80934 | 5 |
View Market Depth
| Last trade - 15.59pm 10/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |